Sunil Abhyankar
Overview
Explore the profile of Sunil Abhyankar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
996
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bansal R, Wiedel A, Hastings R, Boutz F, Abdelhakim H, Ahmed N, et al.
J Clin Apher
. 2025 Jan;
40(1):e70004.
PMID: 39810305
Apheresis is essential to conducting hematopoietic cell transplantation and genetically engineered cellular therapy procedures. Many patients and donors require central venous catheter (CVC) access for apheresis due to lack of...
2.
Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Abboud C, et al.
J Clin Oncol
. 2024 Sep;
43(2):201-213.
PMID: 39298738
Purpose: Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate I-apamistamab...
3.
Shahzad M, Amin M, Bellman P, Al-Ramahi J, Noor J, Vyas A, et al.
Transfusion
. 2024 Jun;
64(8):1402-1406.
PMID: 38847196
Background: Nivestym, a biosimilar granulocyte colony-stimulating factor (G-CSF) to the originator filgrastim (Neupogen), is now being used for the mobilization of peripheral blood stem cells (PBSC) in allogeneic hematopoietic stem...
4.
Aires D, Abhyankar S
Hematol Oncol
. 2023 Nov;
41(5):809-816.
PMID: 37974524
Patients with cutaneous T-cell lymphoma with progressive disease typically undergo a series of skin-directed and systemic therapy regimens during cycles of response and relapse. Extracorporeal photopheresis (ECP) is an effective...
5.
Ahmed N, Wesson W, Mushtaq M, Bansal R, Abdelhakim H, Bromert S, et al.
Front Oncol
. 2023 Aug;
13:1206715.
PMID: 37601685
Background: The first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines of therapy. Despite the promising...
6.
Al Malki M, London K, Baez J, Akahoshi Y, Hogan W, Etra A, et al.
Blood Adv
. 2023 May;
7(17):5189-5198.
PMID: 37235690
Graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract is the main cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Ann Arbor (AA) scores derived from serum biomarkers at...
7.
Umbaugh D, Soder R, Nguyen N, Adelusi O, Robarts D, Woolbright B, et al.
Arch Toxicol
. 2022 Sep;
96(12):3315-3329.
PMID: 36057886
The persistence of hepatotoxicity induced by N-acetyl-para-aminophenol (Acetaminophen or Paracetamol, abbreviated as APAP) as the most common cause of acute liver failure in the United States, despite the availability of...
8.
Maakaron J, Zhang M, Chen K, Abhyankar S, Bhatt V, Chhabra S, et al.
Bone Marrow Transplant
. 2022 Apr;
57(6):911-917.
PMID: 35368040
Acute Myeloid Leukemia (AML) has a median age at diagnosis of 67 years. The most common curative therapy remains an allogeneic hematopoietic stem cell transplantation (HCT), yet it is complicated...
9.
Kuravi S, Baker R, Mushtaq M, Saadi I, Lin T, Vivian C, et al.
NPJ Precis Oncol
. 2022 Jan;
6(1):3.
PMID: 35042970
Gene fusions are known to drive many human cancers. Therefore, the functional characterization of newly discovered fusions is critical to understanding the oncobiology of these tumors and to enable therapeutic...
10.
Zeiser R, Socie G, Schroeder M, Abhyankar S, Vaz C, Kwon M, et al.
Lancet Haematol
. 2021 Dec;
9(1):e14-e25.
PMID: 34971577
Background: Acute graft-versus-host disease (GVHD) is a common and life-threatening complication of allogeneic haematopoietic stem cell transplantation (HSCT); there is an urgent unmet need for effective therapies. We aimed to...